Combretastatin A1 (Synonyms: CA1) |
| Katalog-Nr.GC43300 |
Combretastatin A1 ist ein Inhibitor der Mikrotubuli-Polymerisation, der an die Colchicin-Bindungsstelle von Tubulin bindet. Combretastatin A1 hemmt den Wnt/β-Catenin-Weg durch Tubulin-Depolymerisations-vermittelte AKT-Deaktivierung. Combretastatin A1 zeigt Antitumor- und antivaskuläre Wirkungen.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 109971-63-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Combretastatin A1 is a cis-stilbene originally isolated from C. caffrum that inhibits microtubule assembly (ID50 = 2 µM) by binding to the colchicine binding site on β-tubulin. It inhibits proliferation of hepatocellular carcinoma (IC50s = 9.2-728.2 nM) and other carcinoma cell lines (IC50s = 12.2-2,247 nM). Combretastatin A1 increases apoptosis of HepG2 cells in a GSK3β-dependent manner by decreasing the levels of MCL-1 and β-catenin. It inhibits tumor growth in a hepatocellular carcinoma mouse xenograft model when administered at doses of 2 or 4 mg/kg for 4 weeks. It also enhances the effects of carboplatin , paclitaxel , and cisplatin in murine models of cancer. Combretastatin A1 decreases functional vascular volume within hours in a well-vascularized murine colon adenocarcinoma model.
Average Rating: 5 (Based on Reviews and 33 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *